Evidence map›Paper›PMID 42666945›Full record

ArticleEClinicalMedicine2026

Health-related quality of life after risk-reducing hysterectomy (PRESCORES): a cross-sectional study.

Samuel George Oxley, Milly Lake, Amanda Dibden, Tia Whenham, Xia Wei, Lea Mansour, Ashwin Kalra, Subhasheenee Ganesan, Jacqueline Sia, Michail Sideris and 42 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Samuel George OxleyWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Milly LakeWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Amanda DibdenWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Tia WhenhamWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Xia WeiWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Lea MansourWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Ashwin KalraWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Subhasheenee GanesanWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Jacqueline SiaWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Michail SiderisWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Caitlin FierhellerWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Margarida KurzerDepartment of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, UK.
Rachel Perfect-LakeDepartment of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, UK.
Jyotsna PundirWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Ruth ArmstrongDepartments of Medical Genetics and Paediatric Neurology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Janos BalegaPan-Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, UK.
Ishita BhatnagarOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Michela CicchettiSt Mark's Hospital Centre for Familial Intestinal Cancer, London North West University Healthcare NHS Trust, London, UK.
Cecilia ComptonClinical Genetics Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Jacqueline CookSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Rosemarie DavidsonWest of Scotland Genetic Service, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
Lesa DawsonDepartment of Obstetrics and Gynaecology, The University of British Columbia, Vancouver, Canada.
Sadaf Ghaem-MaghamiImperial College London, London, UK.
Helen HansonPeninsula Clinical Genetics, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Rachel HarrisonDepartment of Clinical Genetics, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Rachel HartLiverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
Alison KrausYorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
Fiona LallooManchester Centre for Genomic Medicine, Manchester University Hospitals Foundation Trust, Manchester, UK.
D Gareth EvansDivision of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
Terri P McVeighCancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Kevin MonahanSt Mark's Hospital Centre for Familial Intestinal Cancer, London North West University Healthcare NHS Trust, London, UK.
Laura Monje-GarciaSt Mark's Hospital Centre for Familial Intestinal Cancer, London North West University Healthcare NHS Trust, London, UK.
Esther MossDepartment of Gynaecological Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Alex MurrayAll Wales Medical Genomics Services, University Hospital of Wales, Cardiff, UK.
Kai Ren OngWest Midlands Regional Genetics Service, Birmingham Women's Hospital, Birmingham, UK.
Myfanwy RawsonManchester Centre for Genomic Medicine, Manchester University Hospitals Foundation Trust, Manchester, UK.
Dimitra RepanaDepartment of Oncology, St George's University Hospitals NHS Foundation Trust, London, UK.
Adam N RosenthalDepartment of Gynaecological Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Neil RyanDepartment of Gynaecology Oncology, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Lyndall SarkiesDepartments of Medical Genetics and Paediatric Neurology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Saba SharifNorth East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Lucy SideWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
Kate SimonNorth East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Tracy SmithLynch Syndrome UK, West Midlands, UK.
Joyce SolomonsOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Vishakha TripathiClinical Genetics Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Amy WatfordDepartment of Clinical Genetics, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Mark WillettDepartment of Gynaecology, East Lancashire Hospitals NHS Trust, Burnley, UK.
Adam BrentnallWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
Rosa LegoodDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK.
Ranjit ManchandaWolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK.
PRESCORES study team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Understanding the impact of risk-reducing hysterectomy (RRH) on health-related quality-of-life is essential for informed decision-making around endometrial cancer prevention and has not been previously investigated. This study aimed to estimate health-related utilities in women who received RRH. Methods: PRESCORES was a multicentre cross-sectional study (ISRCTN17432105). We invited 4031 UK women ≥18 years with confirmed Lynch Syndrome, without prior gynaecological cancer, to participate between May 2023 and November 2024. The main outcome was a complete-case adjusted mean-difference in EQ-5D utility scores between participants who had undergone RRH or not, and by pre/post-menopausal age groups. Quality-of-life was measured at the time of survey completion, and retrospectively 4 months after surgery in the RRH-group. The Cancer-Worry Scale instrument was also evaluated by RRH group. Sensitivity analysis considered alternative statistical methods, multiple imputation, and restricting analysis to people 35-80 years. Findings: Analysis included 1120 participants: 529 had undergone RRH with a median age of 55 years (IQR 48-62), compared with 39 years (33-52) without RRH. The RRH-group was significantly more likely to have had cancer, physical co-morbidities, be parous and used aspirin. Adjusted mean utilities were slightly lower in the RRH than no-RRH group (difference -0.020, 95% CI -0.045 to 0.004; p = 0.11), much lower for premenopausal women (-0.041, -0.074 to -0.008), but similar for postmenopausal women (0.003, -0.036 to 0.042). Cancer-Worry-Scale scores were lower in the RRH group (mean-difference 0.48, 95% CI -0.807 to -0.157; p = 0.0037). Interpretation was robust to sensitivity analyses. Interpretation: Health-related quality-of-life in women with Lynch Syndrome is likely to be lower following RRH in younger, pre-menopausal women. This is relevant for counselling, RRH decision making, and economic evaluations of women with Lynch Syndrome, with increased endometrial cancer risk. Funding: Rosetrees Trust (CF1\100001) and Barts Charity (G-002286 and MRC0167).

Indexed as

HysterectomyLynchMMRQuality-of-lifeRisk-reducingUtilities

Identifiers

PMID42666945
PMCPMC13523832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.